{"id":2347,"date":"2026-07-31T09:45:00","date_gmt":"2026-07-31T13:45:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2347"},"modified":"2026-07-31T20:17:58","modified_gmt":"2026-08-01T00:17:58","slug":"ziltivekimab-misses-phase-3-cardiovascular-endpoint","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2347","title":{"rendered":"Ziltivekimab Misses Phase 3 Cardiovascular Endpoint"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Novo Nordisk<\/p>\n

Event Type<\/strong><\/p>\n

Clinical Trial Results (Phase 3 Cardiovascular Outcomes Trial, Missed Primary Endpoint)<\/p>\n

Modality<\/strong><\/p>\n

Fully human anti-IL-6 ligand monoclonal antibody<\/p>\n

Asset<\/strong><\/p>\n

Ziltivekimab<\/p>\n

Target<\/strong><\/p>\n

Interleukin-6 (IL-6) ligand<\/p>\n

Disease Area<\/strong><\/p>\n

Established atherosclerotic cardiovascular disease with chronic kidney disease and systemic inflammation<\/p>\n

Summary<\/h4>\n

Novo Nordisk reported that the Phase 3 ZEUS cardiovascular outcomes trial did not reduce major adverse cardiovascular events in more than 6,300 adults with established atherosclerotic cardiovascular disease, chronic kidney disease, and persistent systemic inflammation. Ziltivekimab achieved the expected pharmacodynamic effects, including reductions in free interleukin-6 and high-sensitivity C-reactive protein, but the primary three-point MACE result was neutral: hazard ratio 0.99 (95% confidence interval 0.88-1.11).<\/p>\n

The result is a high-importance negative\/mixed signal. It directly weakens the clinical thesis that chronic IL-6 ligand inhibition will reduce cardiovascular events in this selected population, yet it does not by itself invalidate ziltivekimab in heart failure or immediately after myocardial infarction. Those settings are being tested separately. A higher incidence of serious infections adds a safety consideration that could further narrow the viable benefit-risk window.<\/p>\n

ZEUS randomized patients to once-monthly subcutaneous ziltivekimab 15 mg or placebo on top of standard care. Eligible patients had established atherosclerotic cardiovascular disease, stage 3 or 4 chronic kidney disease, and high-sensitivity C-reactive protein of at least 2 mg\/L. The primary endpoint was time to first cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.<\/p>\n

The study did not meet that endpoint. Overall adverse events and serious adverse events were reported as similar between groups, but serious infections occurred more often with ziltivekimab. All-cause mortality did not differ. Detailed event counts, infection types, discontinuations, subgroup results, and complete statistical analyses remain undisclosed pending presentation at a 2026 scientific meeting. The separate HERMES heart-failure and ARTEMIS post-myocardial-infarction trials continue, with readouts expected in the first half of 2027.<\/p>\n

Mechanistic read-through<\/h4>\n

ZEUS created a stringent test of the residual-inflammatory-risk hypothesis. The population was enriched for cardiovascular and renal risk and for systemic inflammation, while the drug achieved its intended biomarker effect. The absence of a MACE signal therefore cannot be readily attributed to a failure to engage the IL-6 pathway. The cleanest interpretation is that lowering circulating IL-6 activity and hsCRP was insufficient to alter the causal biology driving recurrent events in this chronic, intensively treated setting. That conclusion must still be bounded: hsCRP is an integrative inflammatory marker, not a pathway-specific companion diagnostic, and patients may have reached an advanced disease stage dominated by thrombosis, plaque architecture, renal dysfunction, or non-IL-6 inflammatory circuits.<\/p>\n

Benefit-risk and development implications<\/h4>\n

The serious-infection imbalance is biologically plausible for sustained IL-6 suppression and matters even in the absence of an all-cause mortality difference. If the absolute infection excess is meaningful, a modest cardiovascular benefit would have been required to justify chronic preventive treatment; ZEUS showed no such benefit at the primary endpoint level. The result raises the evidentiary bar for HERMES and ARTEMIS but does not predetermine them, since heart failure and the early post-infarction period may involve more acute IL-6-dependent inflammation than stable atherosclerotic disease with kidney dysfunction.<\/p>\n

Competing interpretations<\/h4>\n

One interpretation is true mechanistic failure in chronic cardiovascular prevention, supported by the large randomized design, high-risk inflammatory enrichment, verified pathway suppression, and a point estimate essentially equal to one. A second interpretation is that this reflects context or timing failure rather than modality-wide failure, since acute myocardial infarction and inflammatory heart failure have different pathophysiology and potential responsiveness to immune modulation; however, a large outcomes trial with strong target engagement failing to show even directional benefit, combined with increased serious infections, lowers the prior probability that later programs will show a favorable net effect.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • ZEUS did not reduce three-point MACE; hazard ratio 0.99 (95% CI 0.88-1.11).<\/li>\n
  • Ziltivekimab lowered free IL-6 and hsCRP as expected, separating pharmacodynamic activity from clinical outcome.<\/li>\n
  • Serious infections were more frequent with ziltivekimab; detailed numerical safety data are not yet public.<\/li>\n
  • HERMES and ARTEMIS remain ongoing, with results expected in the first half of 2027.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    ZEUS is a decisive clinical failure for ziltivekimab in chronic ASCVD with CKD and systemic inflammation, not a biomarker or execution miss. Target engagement occurred, yet the hard cardiovascular endpoint remained neutral. The result should be interpreted as negative for this indication and mixed for the broader program: HERMES and ARTEMIS test meaningfully different disease windows, but both now need unequivocal clinical outcomes and a favorable infection profile to overcome the ZEUS read-through.<\/p>\n

    Company and Product Background<\/h4>\n

    Novo Nordisk is a global biopharmaceutical company with core franchises in metabolic and cardiovascular disease. Ziltivekimab is a fully human monoclonal antibody that binds the interleukin-6 ligand and is designed for once-monthly subcutaneous administration. By reducing IL-6 signaling, it lowers hepatic production of high-sensitivity C-reactive protein and other inflammatory mediators.<\/p>\n

    ZEUS studied adults with established atherosclerotic cardiovascular disease and stage 3 or 4 chronic kidney disease, a population with high residual event risk despite standard preventive therapy. The biological premise was that persistent IL-6-driven inflammation contributes causally to plaque instability and recurrent cardiovascular events.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance is rated 5\/5, given that a large Phase 3 outcomes trial missed a hard clinical endpoint despite confirmed target engagement, creating a direct portfolio and field-level read-through. Signal Direction is Negative\/mixed: negative for the ZEUS indication and the use of hsCRP lowering as a clinical-benefit proxy, mixed for the broader ziltivekimab program because HERMES and ARTEMIS remain independent tests. Confidence in the facts is High. Confidence in the interpretation is High for the conclusion that ZEUS failed and materially weakens the chronic-prevention thesis, and Medium-High for broader mechanistic or portfolio extrapolation.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Novo Nordisk reported that the Phase 3 ZEUS cardiovascular outcomes trial did not reduce major adverse cardiovascular events in more than 6,300 adults with established atherosclerotic cardiovascular disease, chronic kidney disease, and persistent systemic…<\/p>\n","protected":false},"author":1,"featured_media":2352,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[154,106],"class_list":["post-2347","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-cardiovascular-disease","tag-novo-nordisk"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2347","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2347"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2347\/revisions"}],"predecessor-version":[{"id":2359,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2347\/revisions\/2359"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2352"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2347"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2347"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2347"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}